NSCLC patients with MET exon 14 skipping mutation are often affected in people of an average age of over 70 years or older, dissimilar in cancerous patients with other oncogene-driven forms of NSCLC [10]. This evidence concerns the gene MET and non-small cell lung carcinoma.